Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
396 USD | +0.64% | -0.30% | -2.83% |
Apr. 18 | Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain | MT |
Apr. 17 | UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.83% | 102B | |
+1.93% | 96.07B | |
-1.60% | 21.66B | |
-17.49% | 20.77B | |
-6.87% | 18.53B | |
-40.31% | 16.91B | |
-27.68% | 13.79B | |
+0.52% | 13.33B | |
+21.09% | 10.94B | |
-21.99% | 8.57B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Piper Sandler Assumes Vertex Pharmaceuticals at Overweight With $385 Price Target